Navigation Links
Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008
Date:1/5/2009

Both Definity(R) and OptisonTM Usage Increased During the Same Study Period, According To New Data from Arlington Medical Resources

MALVERN, Pa., Jan. 5 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the number of micro-bubble echo contrast procedures performed in October 2008 have increased by more than 50 percent, to nearly 18,000 procedures, when compared to May 2008. Micro-bubble echo contrast procedures began declining sharply in October 2007, from nearly 55,000 procedures in September 2007, as a result of a black box warning issued by the FDA in October 2007.

A revised black box warning issued in May 2008 has contributed to this rebound as well as physicians and sonographers reestablishing protocols for contrast usage in their institutions. A micro-bubble echo contrast agent is administered intravenously and used for contrast enhancement during echocardiographic procedures.

The newly released edition of the U.S. Echocardiography Monthly Monitor also finds that both Lantheus Medical Imaging's Definity(R) and GE Healthcare's OptisonTM -- the two FDA approved micro-bubble echo contrast agents -- realized increased usage during the same study period.

"Continued interest in ultrasound contrast is evident with the recently released American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Agents in Echocardiography and the formation of the International Contrast Ultrasound Society (ICUS)," stated Anna Fisher, analyst at AMR.

Why Pharmaceutical & Medical Device Companies Need this Information

The U.S. Echocardiography Monthly Monitor enables pharmaceutical and medical device companies to monitor the utilization rates of echocardiography in the U.S. It is the timeliest data available to gauge movement and direction of the volume of echocardiography studies being performed and cardiac ultrasound contrast agent and pharmacological stressing agent usage.

About the U.S. Echocardiography Monthly Monitor

The U.S. Echocardiography Monthly Monitor is a monthly syndicated audit of echocardiography procedures, ultrasound contrast agents and pharmacologic stress agents used in hospitals and office-based cardiology settings. The study quantifies echocardiography procedure volumes on a national scale, split by type of echo, contrast/non-contrast, type of contrast and stressing method where applicable. The data is available 30 days after the end of each study month.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales
    Decision Resources
    781-296-2691
    nmorales@dresources.com

    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Association Endorses Recommendations for Contrast Agent Use in Heart Ultrasounds (Echocardiograms)
2. A breakthrough in contrast-enhanced intraoperative ultrasonography
3. Allergic-like reactions to iodinated contrast material treated safely with commonly used medications
4. CCNY researchers demonstrate effectiveness of contrast agent Cytate in detectcing prostate cancer
5. Whole Milk Cheaper, Effective Contrast Agent for GI Scans
6. NOVA(R) Renal: A Safe Alternative to Contrast Enhanced MRA/MRI
7. Whole milk is effective and cost-effective as oral contrast agent
8. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
9. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
10. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
11. DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRis Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: